The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes of DLBCL, follicular lymphoma (FL) and Richter transformation (RT) patients treated with ibrutinib: A real-world experience of off-label ibrutinib use.
 
Krista Isaac
No Relationships to Disclose
 
Kaitlin Kennard
No Relationships to Disclose
 
Daniel Jeffrey Landsburg
Leadership - Curis
Research Funding - Curis
 
Mitchell E. Hughes
No Relationships to Disclose
 
Jakub Svoboda
Consulting or Advisory Role - Seagen
Research Funding - Bristol-Myers Squibb; Celgene; Merck; Pharmacyclics; Seagen
Travel, Accommodations, Expenses - Merck
 
Sunita Nasta
Research Funding - Millennium
 
Tanya Latorre
No Relationships to Disclose
 
William Surkis
No Relationships to Disclose
 
Molly J Fanning
No Relationships to Disclose
 
Elizabeth Chatburn
No Relationships to Disclose
 
Colleen Dorsey
Consulting or Advisory Role - Janssen; TG Therapeutics
 
Catherine Daniel
No Relationships to Disclose
 
Colleen Timlin
No Relationships to Disclose
 
Jennifer Gill
No Relationships to Disclose
 
Stephen J. Schuster
Consulting or Advisory Role - Celgene; Gilead Sciences; Nordic Nanovector; Novartis; Pharmacyclics
Research Funding - Celgene (Inst); Gilead Sciences (Inst); Johnson & Johnson (Inst); Novartis (Inst); Pharmacyclics (Inst)
 
Anthony R. Mato
Consulting or Advisory Role - Celgene; Genentech; Gilead Sciences; Pharmacyclics; Regeneron
Research Funding - Abbvie; Acerta Pharma; DTRM; Gilead Sciences; Pharmacyclics; Regeneron; TG Therapeutics